Abstracts Archive - Page 555 of 2607 - ACR Meeting Abstracts

Abstract Number: 1065 • ACR Convergence 2022
Biosamples from VEDOSS Patients Show Pathological Signs of SSc: Opportunity for a Biololgical Diagnosis of Disease
Rebecca Ross¹, Emily Clarke¹, Will Merchant¹, Panji Mulipa¹, Natalia Riobo-DelGaldo¹ and Francesco Del Galdo², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: The VEDOSS study has recently indicated that more than 50% of patients affected by Raynaud’s phenomenon (RP) and specific SSc anti-nuclear antibodies (ANA) and/or…
Abstract Number: 1067 • ACR Convergence 2022
Analysis of the Transcriptomic Profiles of Rheumatic Skin Diseases Reveals Disease-specific Endotypes
Sneha Shrotri¹, Kathryn Kingsmore Allison¹, Prathyusha Bachali², Amrie Grammer³ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Redmond, WA, ³AMPEL LLC, Charlottesville, VA
Background/Purpose: Patients with rheumatic skin diseases such as cutaneous lupus erythematosus (CLE) and systemic sclerosis (SSc) can be classified from individuals with healthy skin using…
Abstract Number: 1078 • ACR Convergence 2022
Glucocorticoid Use and Related Adverse Events in ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis
Emil De Gomma¹, Peter Merkel², Michael George³, Rennie Rhee³, Andreas Kronbichler⁴, David Jayne⁵, Huibin Yue¹ and Pirow Bekker¹, ¹ChemoCentryx, San Juan Capistrano, CA, ²U of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Cambridge University, Sale Creek, TN, ⁵University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Although the 2021 ACR/VF guidelines for ANCA-associated vasculitis (AAV) recommend reduced-dose glucocorticoids (GCs) over standard-dose GCs (1), this approach still leads to substantial toxicity,…
Abstract Number: 1077 • ACR Convergence 2022
Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
Pirow Bekker¹, Peter Merkel² and David Jayne³, ¹ChemoCentryx, San Juan Capistrano, CA, ²U of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Avacopan is approved as adjunctive treatment for adults with ANCA-associated vasculitis (AAV). This study aimed to combine and report on data of the safety…
Abstract Number: 1076 • ACR Convergence 2022
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Naomi Patel¹, David Jayne², Peter Merkel³, Pirow Bekker⁴, yuqing zhang⁵, Huibin Yue⁴ and John Stone⁶, ¹Massachusetts General Hospital, Sale Creek, TN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴ChemoCentryx, San Juan Capistrano, CA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
Abstract Number: 1070 • ACR Convergence 2022
Discordance of Patient, Physician and Nurse Practitioner Assessment of Disease Burden in Systemic Sclerosis
Maylen Nordgård Carstens¹, Håvard Fretheim¹, Imon Barua¹, Henriette Didriksen², Torhild Garen¹, Øyvind Midtvedt¹, Øyvind Molberg³ and Anna-Maria Hoffmann-Vold¹, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Moss, Norway, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Assessment of disease burden is crucial in the management of systemic sclerosis (SSc). The patient global assessment (PatGA) is a patient self-reported measure widely…
Abstract Number: 1082 • ACR Convergence 2022
Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
Pratyusha Banik¹, Marcia Friedman², Daniela Ghetie³, Dongseok Choi⁴ and Margaret Brophy¹, ¹Oregon Health & Science University, Portland, OR, ²Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, ³Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Lake Oswego, OR, ⁴OHSU-PSU School of Public Health, Portland, OR
Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data…
Abstract Number: 1083 • ACR Convergence 2022
Treatment of ANCA-associated Vasculitis with Extreme Impairment of Renal Function: A Case-Control Study Comparing an Intensive B Cell Depletion Regimen with the Standard of Care Using Oral Cyclophosphamide
Dario Roccatello¹, Savino Sciascia², Stefano Murgia¹, Giacomo Quattrocchio¹, Michela Ferro¹, Emanuele De Simone¹, Carla Naretto¹, Antonella Barreca¹, Daniela Rossi¹, Vittorio Modena¹ and Roberta Fenoglio¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitis associated with antineutrophil cytoplasm antibodies (AAV) in…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
Abstract Number: 1081 • ACR Convergence 2022
Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
Elizabeth Nettleton¹, Sebastian Sattui², Zachary Wallace³ and Mike Putman¹, ¹The Medical College of Wisconsin, Milwaukee, WI, ²University of Pittsburgh, Pittsburgh, PA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that may affect patients with ANCA vasculitis (AAV). Current guidelines conditionally recommend PJP prophylaxis for patients…
Abstract Number: 1094 • ACR Convergence 2022
Mechanical Loading-induced BHLHE40 Promotes Inflammatory Arthritis
Eric Gracey¹, Carolien Vlieghe², Isabelle Cambre¹, Elisabeth Gilis¹, Flore Stappers³, Guillaume Planckaert¹, Rik Lories⁴, Aline Bozec⁵ and Dirk Elewaut⁶, ¹Ghent University, Gent, Belgium, ²VIB-UGent Center for Inflammation Research, Ghent University, Belgium, Gent, Belgium, ³VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium, ⁴KU Leuven, Leuven, Belgium, ⁵Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium
Background/Purpose: Force induced microdamage to joint tissue is hypothesized to trigger inflammatory events in the joint leading to arthritis. Patients with inflammatory arthritis, such as…
Abstract Number: 1088 • ACR Convergence 2022
Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
Eveline Wu¹, Elizabeth McInnis², Sarah Lewis², Mary Collie², Lauren Blazek², Kristin Kennedy², Yichun Hu², Susan Hogan², Candace Henderson², Caroline Poulton², Dhruti Chen², Vimal Derebail², J Charles Jennette³, Ronald Falk² and Donna Bunch², ¹University of North Carolina, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³Department of Pathology and Laboratory Medicine, The University of North Carolina Chapel Hill, Chapel Hill, NC
Background/Purpose: Evidence is accumulating that alternative complement pathway activation is important in ANCA vasculitis pathogenesis. Our group was the first to show that complement activation…
Abstract Number: 1090 • ACR Convergence 2022
Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging
Johannes Dieterich¹, You-Shan Feng², Juliane Mahrhold¹, Abdallah El Rai³ and Bernhard Hellmich¹, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²Institute for clinical Epidemiology and Biometry, University of Tübingen, Tübingen, Germany, ³Department of Radiology und Nuclear Medicine, Medius Kliniken, University of Tübingen, Nürtingen, Germany
Background/Purpose: Although pulmonary manifestations occur frequently in AAV, empirical evidence of their impact on pulmonary function is scarce. This project analyzed PFT data from a…
Abstract Number: 1086 • ACR Convergence 2022
Characteristics and Outcomes of Patients with ANCA Associated Vasculitis Treated with Plasma Exchange: An Analysis of the National Inpatient Sample Database
Vinit Gilvaz¹, Akil Sherif², Sonu Abraham³, Anu Saji² and Anthony Reginato⁴, ¹Brown University, East Providence, RI, ²Saint Vincent Hospital, Worcester, MA, ³Lahey Medical Center, Burlington, MA, ⁴Brown University, Providence, RI
Background/Purpose: Plasma exchange (PLEX) has been used in the management of patients with severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) for decades. The most recent…
Abstract Number: 1096 • ACR Convergence 2022
IL-23 Induced Growth Differentiation Factor 15 Contributes to Trabecular Bone Loss, but Does Not Affect Skin, Gut or Joint Inflammation in Psoriatic Arthritis
Renée Van der Cruyssen¹, Djoere Gaublomme¹, Emilie Dumas¹, Carolien Vlieghe¹, Flore Stappers², Julie Coudenys¹, Tine Decruy¹, Lars Vereecke¹, Eric Gracey¹ and Dirk Elewaut³, ¹VIB-UGent Center for Inflammation Research, Ghent University, Belgium, Gent, Belgium, ²VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium
Background/Purpose: IL-23 mediated inflammatory diseases such as psoriasis and psoriatic arthritis are associated with bone loss in addition to more classical features such as skin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].